Table 2 Scores on experienced continuity and health and service outcomes stratified by phase of cancer treatment at recruitment
Treatment phase | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
All ( N =199) | Phase 1 diagnosis ( N =46) | Phase 2 completion first treatment ( N =46) | Phase 3 In remission ( N =47) | Phase 4 On relapse ( N =26) | Phase 5 Specialist palliative care ( N =34) | ||||||||||||||
N | Mean | s.d. | N | Mean | s.d. | N | Mean | s.d. | N | Mean | s.d. | N | Mean | s.d. | N | Mean | s.d. | P -value | |
Continuity of care | |||||||||||||||||||
Total score on 18 statements (range: 0–72) | 181 | 51.8 | 9.9 | 45 | 52.1 | 9.3 | 41 | 50.8 | 12.9 | 41 | 52.1 | 7.9 | 24 | 53.2 | 6.1 | 30 | 51.0 | 11.4 | 0.879 |
Satisfaction | |||||||||||||||||||
Satisfaction (range: 0–50) | 191 | 41.7 | 8.8 | 42 | 41.5 | 8.8 | 46 | 39.3 | 9.9 | 46 | 44.0 | 6.3 | 26 | 43.6 | 6.8 | 31 | 40.8 | 10.8 | 0.086 |
SCNS | |||||||||||||||||||
SCNS Physical and daily living needs (range 0–100) | 194 | 11.7 | 4.7 | 44 | 12.0 | 4.4 | 45 | 11.6 | 4.4 | 46 | 9.4 | 4.1 | 27 | 12.7 | 5.2 | 33 | 13.4 | 4.6 | 0.001 |
SCNS Psychological needs (range 0–100) | 186 | 21.4 | 8.8 | 44 | 21.3 | 9.5 | 44 | 22.8 | 7.9 | 45 | 18.6 | 7.9 | 25 | 25.0 | 10.7 | 28 | 20.6 | 7.2 | 0.037 |
SCNS Patient care+support needs (range 0–100) | 193 | 11.6 | 3.7 | 44 | 12.8 | 4.3 | 46 | 12.2 | 4.2 | 47 | 9.9 | 2.7 | 26 | 11.7 | 3.3 | 30 | 11.6 | 2.9 | 0.003 |
SCNS Health system +information needs (range 0–100) | 184 | 21.8 | 6.9 | 42 | 23.8 | 8.2 | 46 | 24.5 | 8.4 | 47 | 19.1 | 4.9 | 25 | 21.9 | 3.7 | 24 | 19.5 | 4.6 | <0.001 |
SCNS Sexuality needs (range 0–100) | 193 | 4.3 | 2.4 | 44 | 4.7 | 2.3 | 45 | 4.0 | 2.0 | 47 | 4.3 | 3.1 | 25 | 4.3 | 3.1 | 32 | 4.2 | 2.2 | 0.727 |
Euroqol | |||||||||||||||||||
Euroqol ED5D (range: −0.59–1.00) | 196 | 0.67 | 0.5 | 46 | 0.73 | 0.23 | 46 | 0.73 | 0.23 | 47 | 0.78 | 0.13 | 26 | 0.64 | 0.28 | 31 | 0.36 | 1.1 | 0.001 |
Euroqol thermometer (range 0–100) | 190 | 66.6 | 18.9 | 43 | 64.3 | 20.7 | 45 | 69.5 | 16.4 | 45 | 74.8 | 15.8 | 26 | 60.8 | 20.3 | 31 | 58.7 | 18.1 | 0.001 |
GHQ | |||||||||||||||||||
GHQ Total (range 0–28) | 173 | 6.3 | 0.4 | 43 | 7.2 | 0.8 | 39 | 6.9 | 0.9 | 43 | 4.1 | 0.8 | 20 | 8.5 | 1.5 | 28 | 5.7 | 0.9 | 0.01 |
GHQ casenessa | |||||||||||||||||||
Non case | 92 (53.2%) | 16 (37.2%) | 22 (56.4%) | 31 (72.1%) | 9 (45.0%) | 14 (50%) | 0.022 | ||||||||||||
Case | 81 (46.8) | 27 (62.8%) | 17 (43.6%) | 12 (27.9%) | 11 (55.0%) | 14 (50%) | |||||||||||||
